11 Things Women Are Told to Simply Accept at Menopause That Are Actually Modifiable With Evidence-Based Treatment
The phrase 'it's just menopause' has ended more conversations than it should have. What frustrates me most is that the dismissal often comes from a place of genuine misunderstanding — not malice — which means women leave thinking they've been told the truth. They haven't. The evidence for treating these symptoms exists, it's substantial, and women deserve to know about it.
Learn more about Rose →Vaginal Dryness and Painful Sex
Vaginal dryness is caused by falling estrogen levels thinning and drying the vaginal walls — a condition now called genitourinary syndrome of menopause (GSM). Unlike hot flashes, which often ease over time, GSM is progressive and does not resolve without treatment. Low-dose vaginal estrogen, applied locally, is highly effective, carries minimal systemic absorption, and is considered safe even for many women who cannot use systemic HRT.
Sleep Disruption
Women are frequently told that poor sleep is an inevitable feature of midlife aging, but the physiology is more specific than that: fluctuating and declining estrogen and progesterone directly disrupt sleep architecture, reducing slow-wave and REM sleep. Menopausal hormone therapy has been shown in randomised controlled trials to improve subjective and objective sleep quality, particularly in women whose sleep disruption is driven by vasomotor symptoms. For those with primary insomnia independent of hot flashes, CBT-I (cognitive behavioural therapy for insomnia) has strong evidence and should not be bypassed.
Brain Fog and Memory Lapses
Losing words mid-sentence or walking into a room and forgetting why is one of the most distressing and least-acknowledged menopause symptoms, and women are routinely told it is either stress or early dementia. In reality, the brain contains estrogen receptors throughout the regions governing memory, attention, and processing speed, and cognitive changes during perimenopause map closely onto hormonal fluctuation. Observational and some trial data suggest that initiating HRT during the perimenopausal window — rather than years after menopause — may support cognitive function, and the symptoms themselves are widely reported to improve with treatment.
Low Libido
A decline in sexual desire is so commonly dismissed as a natural consequence of aging or relationship duration that many women never raise it with a clinician at all. The physiology is real and specific: testosterone, which governs libido in women as well as men, declines significantly across the menopause transition, and GSM simultaneously makes sex uncomfortable, compounding the problem. Testosterone therapy for low libido in postmenopausal women has a substantial evidence base, with a 2019 global consensus statement from leading endocrinology and menopause societies confirming its efficacy and safety.
Joint Pain and Stiffness
Aching joints — particularly in the hands, knees, and hips — are among the most common and least expected menopause symptoms, and are frequently attributed to 'just getting older' or dismissed as early arthritis. Estrogen has well-documented anti-inflammatory properties and plays a role in maintaining cartilage and connective tissue, which explains why joint symptoms often emerge sharply during perimenopause rather than gradually over decades. Several studies, including analyses from the Women's Health Initiative, found that women using HRT reported significantly less joint pain than those who did not.
Mood Changes, Anxiety, and Low Mood
Women experiencing perimenopausal anxiety, irritability, or low mood are often prescribed antidepressants without any hormonal investigation, despite the fact that these symptoms frequently have a direct hormonal driver. Estrogen modulates serotonin, dopamine, and GABA pathways — the same neurotransmitter systems targeted by antidepressants — and fluctuating estrogen during perimenopause creates measurable instability in these systems. Evidence from RCTs shows that transdermal estradiol can be as effective as antidepressants for low mood during perimenopause, and the British Menopause Society guidelines now acknowledge this distinction explicitly.
Urinary Urgency and Recurrent UTIs
Bladder urgency, frequency, and a pattern of recurrent urinary tract infections after menopause are widely treated as unrelated nuisances rather than interconnected, estrogen-responsive symptoms. The bladder, urethra, and pelvic floor all contain estrogen receptors, and as estrogen falls, these tissues thin and become less resilient — raising susceptibility to both urgency and infection. Local vaginal estrogen has been shown in meta-analyses to significantly reduce the frequency of recurrent UTIs in postmenopausal women, yet it remains dramatically underprescribed for this indication.
Hot Flashes and Night Sweats
The paradox here is that vasomotor symptoms are perhaps the one thing clinicians do acknowledge as menopause-related — yet women are still frequently told to simply wait them out. For a substantial proportion of women, hot flashes persist for seven to ten years or longer, and for some they continue into their sixties and beyond, making passive waiting a poor strategy. MHT remains the most effective treatment available, with consistent RCT evidence showing 75–90% reduction in vasomotor symptom frequency and severity, and non-hormonal options including fezolinetant — a neurokinin B receptor antagonist — now offering an evidence-based alternative for those who cannot use hormones.
Weight Gain, Particularly Around the Abdomen
The shift in fat distribution toward the abdomen at menopause is often presented as an unavoidable feature of aging metabolism, but the hormonal mechanism is distinct and well-characterised: declining estrogen alters how the body stores fat, preferentially directing it to visceral abdominal tissue. This matters beyond appearance — visceral fat is metabolically active and associated with increased cardiovascular and metabolic risk. Evidence from trials indicates that MHT can attenuate menopause-related abdominal fat accumulation, and resistance training has strong independent evidence for preserving lean muscle mass and improving metabolic composition during this transition.
Skin Thinning, Dryness, and Accelerated Aging
Skin contains estrogen receptors, and the years immediately following menopause are associated with a rapid and measurable decline in skin collagen — estimated at around 30% in the first five years. Women are largely told this is aging and directed toward cosmetic products, but the underlying driver is hormonal. Studies show that both systemic and topical estrogen can preserve skin thickness, elasticity, and moisture content, and this is an area of legitimate therapeutic interest that sits entirely within the scope of evidence-based menopause care.
Heart Palpitations
Palpitations during perimenopause are frequently met with normal ECGs and reassurance that nothing is wrong — which, while often accurate, leaves women without an explanation or a path forward. Estrogen has a stabilising effect on cardiac electrical activity, and its fluctuation during perimenopause can trigger benign but distressing palpitations that track closely with hormonal instability rather than intrinsic cardiac disease. While cardiac causes must always be excluded first, evidence supports estrogen's role in cardiovascular regulation, and many women find that stabilising estrogen levels through MHT resolves palpitations that had been written off as anxiety.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.